Singulex Announces Preview of the Sgx Clarity(TM) IVD System and Presentation of 10 Abstracts Demonstrating Single Molecule (SMC(TM)) Technology Performance in Cardiovascular Disease at 2014 ESC Congress

ALAMEDA, Calif., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today announced the presentation of ten abstracts demonstrating the value of SMC technology in cardiovascular disease research at the European Society of Cardiology (ESC) Congress 2014 in Barcelona, Spain, August 30th to September 3rd, coinciding with the preview of the Sgx Clarity™ System (currently under development ). The 10 selected abstracts detail the latest clinical and diagnostic findings made in the area of cardiovascular disease and its comorbidities, made possible by the accurate quantification of biomarkers to unprecedented levels using SMC technology. Three of the ten abstracts have been selected for oral presentation.

"This collection of abstracts exemplifies how high sensitivity biomarker measurements with SMC technology can advance cardiac disease detection and diagnosis," said Dr. Christian Mueller, MD, Professor of Cardiology at University Hospital Basel, Cardiovascular Research Institute Basel, Basel, Switzerland. "In our hands, Singulex's highly-sensitive cardiac troponin I (cTnI) assay demonstrated the potential to not only improve the accuracy of diagnosing coronary artery disease, but that its clinical adoption will add the benefit of identifying which patients may, or may not, need expensive diagnostic procedures, ultimately reducing healthcare costs in cardiovascular disease."

Four of the ten abstracts summarize research findings of studies that use the cTnI assay to investigate the relationship between cTnI and heart failure, coronary heart disease, and exercise-induced myocardial ischemia. Five others highlight endothelin-1 (ET-1) and interleukin-6 (IL-6) biomarkers, and discoveries regarding their implications in heart disease and its comorbidities. Two abstracts summarize research that examined the relationship of glucagon like peptide-1 (GLP-1) to blood pressure and body fat mass in young, healthy adults. One abstract features findings of a study that used a kidney injury molecule (KIM-1) assay to determine if there is an association between KIM-1 and renal dysfunction in heart failure patients, as worsening kidney function is a known comorbidity of heart failure. A tenth abstract presents results of a study where the matrix metalloproteinase-9 (pMMP-9) assay was used to evaluate its ability to predict heart failure. Results for all of the above biomarkers were generated on the Singulex Erenna® Immunoassay System, available for Research- Use- Only.

The 2014 ESC Congress also marks the first preview in the EU of Singulex's SMC-driven Sgx Clarity System, a fully-automated in vitro diagnostics system that will be available to European hospitals and reference laboratories targeted for launch in the EU market in 2016. "The proven performance of Singulex's SMC Technology in the European research market with the Singulex Erenna® System will soon be available on the Sgx Clarity System, bringing the power of SMC Technology to diagnostic laboratories across Europe," said Guido Baechler, President and Chief Executive Officer of Singulex. "With the launch of this System, we will also be providing European cardiologists a portfolio of advanced tests that offer unique clinical value in the detection, assessment, and management of CVD patients, and those at risk for the disease."

Singulex invites all ESC Congress attendees to visit their booth located at N160.

About Singulex, Inc.

Singulex is the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex's proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management, and fueling the discovery and development of new therapeutics.

Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex currently is developing the Sgx Clarity™ System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit

CONTACT: Media: Mariesa Kemble 608.850.4745 Investors: Chris Kim Blueprint Life Science Group 415.375.3340 Ext. 101 ckim@bplifescience.comSource: Singulex